Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | GLA | P06280 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MPI | P34949 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL3958008 | 0.92 | KMT2A (0.56) | KDM4EALDH1A1GAAGLALMNA | |
| Benzo[D]Isoxazole SCHEMBL7155431 | 0.83 | KDM4E (0.47) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL3958034 | 0.79 | KDM4E (0.55) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL8105559 | 0.78 | RAB9A (0.54) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL15887220 | 0.78 | KDM4E (1.00) | KDM4EALDH1A1GAAGLALMNA | |
| SCHEMBL862066 | 0.78 | KDM4E (0.51) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL12442815 | 0.78 | KDM4E (0.51) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL13151057 | 0.77 | PKM (0.56) | KDM4ELMNAADORA3ADORA2AADORA2B | |
| SCHEMBL18161342 | 0.77 | KDM4E (0.48) | KDM4EALDH1A1GAAGLAKMT2A | |
| SCHEMBL17297885 | 0.77 | KDM4E (0.48) | KDM4EALDH1A1GAAGLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115557948-A | Method for preparing pyrido [1,2-a ] pyrimidin-4-one compound selenized at C3 position | 淄博职业学院 | 2023-01-03 | — | — | CN | claimed |
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2024138018-A1 | TREATMENT OF GEMIN5-MEDIATED DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| EP-4289813-A2 | INTERMEDIATES TO OBTAIN SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| CN-115557948-A | Method for preparing pyrido [1,2-a ] pyrimidin-4-one compound selenized at C3 position | 淄博职业学院 | 2023-01-03 | — | — | CN | disclosed |
| WO-2022254216-A1 | COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT | STORM THERAPEUTICS LTD (GB) | 2022-12-08 | — | — | WO | disclosed |
| US-5908844-A | N-substituted azabicycloalkane derivatives, their preparation and use | BASF AKTIENGESELLSCHAFT (DE) | 1999-06-01 | — | — | US | disclosed |
| EP-0647231-B1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AG (DE) | 1997-08-27 | — | — | EP | disclosed |
| EP-0775135-A1 | N-SUBSTITUTED 3-AZABICYCLO (3.2.0)HEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS | BASF AKTIENGESELLSCHAFT (DE) | 1997-05-28 | — | — | EP | disclosed |
| EP-0728136-A1 | N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-28 | — | — | EP | disclosed |
| WO-1996004272-A1 | N-SUBSTITUTED 3-AZABICYCLO (3.2.0)HEPTANE DERIVATIVES USEFUL AS NEUROLEPTICS | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-15 | — | — | WO | disclosed |
| US-5475105-A | N-substituted azabicycloheptane derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| WO-1995013279-A1 | N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | BASF AKTIENGESELLSCHAFT (DE) | 1995-05-18 | — | — | WO | disclosed |
| EP-0647231-A1 | N-SUBSTITUTED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AG (DE) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994000458-A1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
| US-3935197-A | 2-Styryl-4H-pyrido(1,2-a)pyrimidin-4-ones | E. R. SQUIBB & SONS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | KDM4E 2384/4885ALDH1A1 1088/4885GAA 13/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | KDM4E 107/4885ALDH1A1 2056/4885GAA 750/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | KDM4E 107/4885ALDH1A1 2056/4885GAA 750/4885 |
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | CBR1, CBR3, CNR1 | KDM4E 3223/4885ALDH1A1 628/4885GAA 4225/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | KDM4E 1370/4885ALDH1A1 1651/4885GAA 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.